β-D-Galactose pentaacetate

β-D-Galactose pentaacetate is a negative regulator of insulin with plasma membrane penetrating ability and can be hydrolyzed by intracellular esterases. β-D-Galactose pentaacetate inhibits Leucine (HY-N0486) -induced insulin release in Wistar rat islets, potentially preventing excessive insulin release in pathological conditions[1][2][3].

Product Specifications

CAS Number

[4163-60-4]

UNSPSC

12352200

Hazard Statement

H302, H315, H319, H335

Target

Insulin Receptor

Type

Biochemical Assay Reagents

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/β-d-galactose-pentaacetate.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic) |Methanol : 16.67 mg/mL (ultrasonic)

Smiles

CC(O[C@H]1[C@H]([C@H](O[C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)OC(C)=O)=O

Molecular Formula

C16H22O11

Molecular Weight

390.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Malaisse WJ, et al. Inhibition of insulin release by alpha- and beta-D-galactose pentaacetate. Int J Mol Med. 1998 Sep;2 (3) :331-2.|[2]Malaisse WJ, et al. Insulinotropic action of beta-L-glucose pentaacetate. Am J Physiol. 1998 Dec;275 (6) :E993-E1006.|[3]Kadiata MM, Malaisse WJ. Opposite effects of D-glucose pentaacetate and D-galactose pentaacetate anomers on insulin release evoked by succinic acid dimethyl ester in rat pancreatic islets. Life Sci. 1999;64 (9) :751-4.